Literature DB >> 14658985

Treating depression to remission.

John M Zajecka1.   

Abstract

Over the last several years, the recommended end point in the treatment of depression has become remission. Patients who achieve remission not only enjoy the benefits of decreased disability and improved functioning in work, family, and social situations, they also have a lower risk of disease progression and relapse. Despite the benefits associated with remission, many patients are left with residual symptoms that prevent them from achieving these benefits. Potential obstacles to reaching remission include diagnostic issues, inadequate treatment, lack of adherence to the treatment regimen, satisfaction with partial improvement, and failure to recognize residual symptoms. Strategies for treating to remission include ensuring appropriate diagnosis, setting treatment goals, selecting antidepressants that are more likely to result in remission, providing patient education and adequate treatment, assessing for residual symptoms, and heeding partial response or lack of response by switching or augmenting treatment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14658985

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  8 in total

Review 1.  Ketamine as a promising prototype for a new generation of rapid-acting antidepressants.

Authors:  Chadi G Abdallah; Lynnette A Averill; John H Krystal
Journal:  Ann N Y Acad Sci       Date:  2015-02-27       Impact factor: 5.691

2.  Complementary use of tai chi chih augments escitalopram treatment of geriatric depression: a randomized controlled trial.

Authors:  Helen Lavretsky; Lily L Alstein; Richard E Olmstead; Linda M Ercoli; Marquertie Riparetti-Brown; Natalie St Cyr; Michael R Irwin
Journal:  Am J Geriatr Psychiatry       Date:  2011-10       Impact factor: 4.105

Review 3.  Tai Chi and Qigong for the treatment and prevention of mental disorders.

Authors:  Ryan Abbott; Helen Lavretsky
Journal:  Psychiatr Clin North Am       Date:  2013-03

4.  Body mass index and atypical balance as predictors of winter depression remission in cognitive-behavioral therapy and light therapy.

Authors:  Praise Iyiewuare; Kelly J Rohan; Teodor T Postolache
Journal:  J Affect Disord       Date:  2021-09-25       Impact factor: 4.839

5.  Pharmacist-guided pre-emptive pharmacogenetic testing in antidepressant therapy (PrePGx): study protocol for an open-label, randomized controlled trial.

Authors:  Céline K Stäuble; Markus L Lampert; Samuel Allemann; Martin Hatzinger; Kurt E Hersberger; Henriette E Meyer Zu Schwabedissen; Christian Imboden; Thorsten Mikoteit
Journal:  Trials       Date:  2021-12-14       Impact factor: 2.279

6.  Untargeted Plasma Metabolomic Profiling in Patients with Major Depressive Disorder Using Ultra-High Performance Liquid Chromatography Coupled with Mass Spectrometry.

Authors:  Claudia Homorogan; Diana Nitusca; Virgil Enatescu; Philip Schubart; Corina Moraru; Carmen Socaciu; Catalin Marian
Journal:  Metabolites       Date:  2021-07-20

7.  Vilazodone in the treatment of major depressive disorder: efficacy across symptoms and severity of depression.

Authors:  Arif Khan; Angelo Sambunaris; John Edwards; Adam Ruth; Donald S Robinson
Journal:  Int Clin Psychopharmacol       Date:  2014-03       Impact factor: 1.659

8.  The relationship between mental disorders and actual and desired subjective social status.

Authors:  Y A de Vries; M Ten Have; R de Graaf; S van Dorsselaer; N M P de Ruiter; P de Jonge
Journal:  Epidemiol Psychiatr Sci       Date:  2019-12-16       Impact factor: 6.892

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.